Development of a new drug to help control bowel and bladder function
Preclinical and Early Clinical Development of a Novel Drug for On-Demand Voiding
This study is testing a new drug called DTI-117 that hopes to help people with spinal cord injuries, multiple sclerosis, or stroke regain control over their bowel and bladder functions, making it easier for them to manage incontinence and retention issues.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dignify Therapeutics, LLC NIH-funded |
| Lab location | 1 site (Research Triangle Park, United States) |
| Project ID | NIH-11074628 on NIH RePORTER |
What this research studies
This research focuses on developing a novel drug that aims to restore voluntary control over bowel and bladder functions for patients suffering from conditions like spinal cord injury, multiple sclerosis, and stroke. The drug, known as DTI-117, is designed to work quickly, inducing voiding within minutes. The research involves preclinical studies and aims to file for an Investigational New Drug Application, eventually leading to early clinical trials. Patients may benefit from a more effective management of incontinence and retention issues.
Who could benefit from this research
Good fit: Ideal candidates include individuals with spinal cord injuries, multiple sclerosis, Parkinson’s disease, spina bifida, stroke, or age-related complications affecting bowel and bladder function.
Not a fit: Patients without bowel or bladder control issues or those not affected by the specified conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide patients with a rapid and effective treatment option for bowel and bladder control.
How similar studies have performed: Previous research has shown promising results with similar approaches targeting neurokinin receptors for bowel and bladder control, indicating potential for success.
Where this research is happening
Research Triangle Park, United States
- Dignify Therapeutics, LLC — Research Triangle Park, United States (Active)
Researchers
- Principal investigator: Burgard, Edward — Dignify Therapeutics, LLC
- Study coordinator: Burgard, Edward
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.